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Key Messages 
• Compound heterozygous IRF8 mutation R83C/ R291Q is described in a patient 
with frequent respiratory virus infections 
• Immunodeficiency is due to dendritic cell and monocytopenia with 
myeloproliferation and widespread immune dysregulation 
Capsule summary 
A second case of bi-allelic IRF8 mutation confirms that dendritic cell and monocytopenia 
are major mechanisms of immunodeficiency, compounded by NK cell maturation arrest, 
failure of Th1, Th17 and CD8 effector memory cells, reduced somatic hypermutation 
and memory B cell formation 
Keywords  
IRF8, immunodeficiency, dendritic cell, monocyte, myeloproliferation, interferon 
Abbreviations 
IRF8  interferon regulatory factor 8 
TFs   transcription factors 
DBD  DNA-binding domain 
IAD  IRF-associated domain 
EICE   Ets-IRF composite element 
ISRE   IFN-stimulated response element 
AICE  AP-1)-IRF composite element 
DC   dendritic cell  
pDC   plasmacytoid dendritic cell 
cDC   conventional dendritic cell 
CVID   common variable immunodeficiency 
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Abstract 2 
Background 3 
Homozygous K108E mutation of interferon regulatory factor 8 (IRF8) is reported to 4 
cause dendritic cell and monocyte deficiency.  However, more widespread immune 5 
dysfunction is predicted from the multiple roles ascribed to IRF8 in immune cell 6 
development and function.   7 
Objective 8 
We sought to describe the effect on hematopoiesis and immunity of compound 9 
heterozygous R83C/ R291Q mutation of IRF8, present in a patient with recurrent viral 10 
infection, granulo-proliferation and intracerebral calcification.   11 
Methods 12 
Variant IRF8 alleles were identified by exome sequencing and their function tested by 13 
reporter assays.  The cellular phenotype was studied in detail using flow cytometry, 14 
functional immunologic assays transcriptional profiling and antigen receptor profiling. 15 
Results 16 
Both mutations affected conserved residues and R291Q is orthologous to R294, 17 
mutated in the BXH2 IRF8-deficient mouse.  R83C showed reduced nuclear 18 
translocation and neither mutant was able to regulate the Ets/IRF composite element or 19 
interferon-stimulated response element, while R291Q retained BATF/JUN interactions. 20 
Dendritic cell deficiency and monocytopenia were observed in blood, dermis and lung 21 
lavage fluid.  Granulocytes were consistently elevated, dysplastic and hypofunctional.  22 
NK development maturation was arrested.  Th1, Th17 and CD8+ memory T cell 23 
differentiation was significantly reduced, and T cells failed to express CXCR3.  B cell 24 
development was impaired with fewer memory cells, reduced class-switching and lower 25 
frequency and complexity of somatic hypermutation. Cell-specific gene expression was 26 
widely disturbed in interferon and IRF8-regulated transcripts.   27 
Conclusions 28 
This analysis defines the clinical features of human bi-allelic IRF8 deficiency, revealing 29 
a complex immunodeficiency syndrome caused by dendritic cell and monocyte 30 
deficiency combined with widespread immune dysregulation.  31 
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Introduction 32 
 33 
Effective immunity depends upon multiple interacting transcription factors (TFs) that 34 
govern hematopoietic development and immune cell function.  Members of the 35 
interferon regulatory factor (IRF) family of TFs have a dual role, interacting with 36 
hematopoietic TFs to determine cell fate and with immune signaling molecules to direct 37 
cell responses1.  IRF4 and IRF8 are structurally related family members with an N-38 
terminal DNA-binding domain (DBD) and C-terminal IRF-associated domain (IAD)2.  39 
They activate or repress transcription at specific DNA motifs in collaboration with other 40 
TFs interacting with the IAD. 41 
 42 
IRF8 heterodimerization partners include SPI1/PU.1 which binds the Ets-IRF composite 43 
element (EICE) frequently activating gene expression.  Other IRF family members 44 
(IRF1,2,4) are co-factors at the mostly repressive IFN-stimulated response element 45 
(ISRE)3, 4.  IRF8 forms a complex with BATF3 and JUN on the activating protein-1 (AP-46 
1)-IRF composite element (AICE) to activate gene expression5.  IRF8 plays a critical 47 
role in hematopoietic lineage determination through these interactions, governing the 48 
development of granulocytes, dendritic cells, monocytes and B cells, reviewed in6, 7.  49 
 50 
In myeloid cell development, IRF8 is pivotal in determining granulocyte versus 51 
monocyte fate.  IRF8 competes with CEBPA for binding to chromatin, resulting in 52 
attenuation of neutrophil differentiation in granulocyte-monocyte progenitors (GMPs)8.  53 
IFR8/PU.1 interaction is critical in monocyte differentiation by marking distal enhancers 54 
for subsequent activation by the master regulator KLF49.  The Irf8-/- mouse develops 55 
massive expansion of granulocytes and progression to fatal myeloblastic leukemia10. 56 
Ly6C+ and Ly6C- monocytes are depleted but some tissue macrophages persist11.  The 57 
BXH2 mouse is homozygous for Irf8R294C mutation in the IAD region of the gene, 58 
disrupting association with heterodimerization partners.  Monocytes and macrophages 59 
are present but rendered hypofunctional in their response to IFNγ12, production of 60 
inflammatory cytokines13 and defense against intracellular infection4, 14.  These two 61 
models illustrate the dual hematopoietic and immune response roles of IRF8 and their 62 
differential sensitivity to IRF8 deficiency.  63 
 64 
Dendritic cells (DCs) are critical for activation of the immune response and arise 65 
independently of monocytes.  All mammalian species have IFNα-producing 66 
plasmacytoid DCs (pDCs) and two myeloid or ‘conventional’ populations (cDCs)15.  67 
Conventional DC1s express  CLEC9A/XCR1 and are specialized for cross-presentation 68 
whereas cDC2s express SIRPA, and mediate Th2 and Th17 responses.  In humans 69 
they are marked by CD141 and CD1c, respectively16.  In mice, IRF8 specifies DC 70 
lineage in co-operation with Id217.  IRF8 is also up-regulated by E2-218 and is required 71 
for pDC development and function19,20.  In cDC1, it interacts with BATF3 to maintain 72 
terminal differentiation21.  The Irf8-/- mouse lacks cDC1s and has reduced pDCs 73 
whereas selective loss of cDC1s is observed in the hypomorphic BXH2 mouse.  74 
Conventional DC2s are preserved in both IRF8 deficient strains through their reciprocal 75 
dependence on IRF422. 76 
 77 
In B cell development, the balance between IRF8 and IRF4 mirrors that observed in the 78 
specification of myeloid DCs subsets.  IRF8 and IRF4 act redundantly to drive pre-B cell 79 
development but are differentially required to regulate marginal zone versus follicular 80 
fate.  IRF8 is important in the germinal center reaction and class switch recombination 81 
while IRF4 is necessary for plasma cell differentiation23, 24.  82 
 83 
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IRF8 also directly influences the terminal differentiation of NK and T cells.  Defects in 84 
NK maturation and function were recently reported in patients with IRF8 mutations25.  85 
Investigation of the Irf8-/- mouse has identified defects in T cell subset differentiation.  86 
IRF8 is required for Th1 polarization, CD8+ T effector memory cell differentiation26, 27 87 
and generation of a Th1-associated subset of Treg cells28, with conflicting reports of the 88 
influence of IRF8 on Th17 polarization29, 30.  89 
 90 
Human primary immunodeficiencies resulting from single gene mutations offer unique 91 
opportunities to study development and regulation of immune cells in vivo.  An infant 92 
with impaired immunity to mycobacteria, viruses and fungi due to a homozygous K108E 93 
mutation of IRF8 was previously described31,32.  The human phenotype was broadly 94 
reminiscent of Irf8-/- mice except that cytopenia encompassed all DC and monocyte 95 
subsets.  Analysis was complicated by environmental factors of disseminated BCG 96 
infection and cyto-reductive therapy and wider cell-specific immune defects were not 97 
studied.  Here we describe two novel alleles of IRF8 in a compound heterozygous 98 
patient who was ambulatory between infective exacerbations.  This reveals a complex 99 
immunodeficiency syndrome comprising profound hematological defects with 100 
widespread immune dysregulation.  101 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
Materials & Methods  102 
Study Approval 103 
The study was performed in accordance with the Declaration of Helsinki and approved 104 
by Newcastle and North Tyneside Research Ethics Committee.  Written informed 105 
consent was obtained from participants prior to recruitment. 106 
Whole exome sequencing 107 
Details of whole exome sequencing and analysis are described in Supplementary 108 
Materials. 109 
Serum auto-antibody analysis across human protein microarray  110 
Sera from the patient and two age-matched controls were incubated on HuProt™ 111 
human protein microarrays (CDI Laboratories, Baltimore, MD).  Details are available in 112 
Supplementary Materials.  113 
Luciferase reporter assays 114 
Expression constructs encoding human PU.1, SPIB, BATF and IRF1 have been 115 
described elsewhere33,34.  Human JUNB, IRF8 wild-type and mutated cDNA sequences 116 
preceded by an HA epitope tag were purchased from GenScript and cloned into 117 
pIRES2-EGFP expression vectors (Clontech).  Luciferase reporter constructs are 118 
described in Supplementary Materials.  HeLa cells were seeded at 1x105 cells/well in 119 
24-well plates with RPMI plus 10% FBS and transfections were performed in triplicate 120 
with GeneJuice (Novagen).  20ng of expression vectors were co-transfected with 150ng 121 
of firefly luciferase vector and 1 ng pRL-CMV Renilla luciferase control.  For each 122 
condition, the total amount of vector transfected was normalized by inclusion of control 123 
pIRES2-EGFP empty vector.  Luciferase activity was assayed 24h post transfection 124 
using the Promega luciferase dual assay system and analyzed on a Berthold Lumat LB 125 
Luminometer.  For each condition, luciferase activity was expressed relative to the 126 
average reading from the empty vector transfections, normalized to ‘1’.  Comparable 127 
expression of IRF8 wild-type and variant alleles by transected cells was confirmed by 128 
immunoblotting for the HA epitope tag. 129 
EMSA  130 
Nuclear extracts were prepared from HeLa cells transfected with expression vectors for 131 
PU.1, SPIB, IRF1, BATF, JUNB, IRF8 WT, IRF8 R83C or IRF8 R291Q as described 33.  132 
Double-stranded DNA probes end-labelled with [γ-32P] ATP using T4 polynucleotide 133 
kinase were incubated with appropriate nuclear extract in the presence of poly(dI:dC) 134 
(Amersham Biosciences) for 30min at room-temperature.  The probes are detailed in 135 
Supplementary Materials. 136 
IRF8 protein analysis 137 
HeLa cells were transfected with the IRF8 constructs using Gene Juice as described 138 
above.  24 h following transfection whole cell lysates were prepared using RIPA buffer 139 
(20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium 140 
deoxycholate).  Alternatively, subcellular fractions were prepared using NE-PER™ 141 
Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher Scientific) according to 142 
the manufacturer’s instructions. Whole cell equivalents or separated fractions were run 143 
on a 10% SDS-PAGE gel, transferred to nitrocellulose and probed with antibody to HA 144 
(Ab9110, Abcam), IRF8 (sc-13043, Santa Cruz Biotechnology), α-ACTIN (Clone AC-15, 145 
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Sigma) or α-TUBULIN (DMIA, Millipore) and subsequently detected by HRP-coupled 146 
secondary antibody and ECL reagent (ThermoFisher Scientific). 147 
Cell culture and functional assays 148 
PBMC were prepared by density-gradient centrifugation and neutrophils were harvested 149 
from the red-cell/granulocyte layer according to standard protocols.  Skin from the 150 
patient and controls undergoing mammoplasty surgery was processed as previously 151 
described35. Dihydrorhodamine oxidative burst was performed with Phagoburst™ 152 
(Glycotope Biotechnology).  Phytohemagglutinin (PHA) responses were determined by 153 
incorporation of tritiated thymidine after 6 days of culture.  Whole blood cytokine assays 154 
were performed as previously described36.   155 
 156 
Cytokines and chemokines in serum and BAL supernatants were measured with 157 
Luminex® using with ProcartaPlex™ 34-plex Immunoassay (EBioscience) on Qiagen 158 
Liquichip 200 running Luminex 100 integrated system software V2.3.  Standard curves 159 
were constructed to interpolate analytes using Procartaplex Analyst version 1.0.  The 160 
mean of technical duplicates was recorded. 161 
 162 
Intracellular cytokine measurement was performed on sorted T cell subsets.  50,000 163 
cells in 200µl of RPMI plus 10% fetal bovine serum (FBS) were stimulated for 3h with 164 
0.02 µg/ml PMA (Sigma-Aldrich) and 0.5 µg/ml ionomycin (Sigma-Aldrich) at 37ºC 165 
followed by 2 µg/ml brefeldin A (Sigma-Aldrich) for a further 3h.  Cells were washed and 166 
stained for intracellular cytokines after permeabilization with FOXP3 staining buffer 167 
(eBioscience).  168 
Flow cytometry and microscopy 169 
PBMC and skin mononuclear cell preparations or lymphoblastoid cell lines were stained 170 
in aliquots of 1-3x106 cells in 50µl of DPBS with 2% fetal calf serum and 0.4% EDTA.  171 
Dead cells, usually <5%, were excluded by DAPI (Partec).  Intracellular IRF8 staining 172 
was performed after fixation and permeabilization as per manufacturer’s instructions 173 
(eBioscience).  Analysis was performed with a LSRFortessa X-20 and sorting with a 174 
FACSAria III (BD Biosciences).  Data were processed with FlowJo (Tree Star, Inc).  175 
Absolute cell counts were obtained using TruCount™ tubes (BD Biosciences) using 176 
200µl whole blood with 900 µl of lysis buffer.  Fluorescence microscopy of epidermal 177 
sheets and cytospin and Giemsa staining of PBMC was performed as previously 178 
described36 using an Axioplan 2 microscope (Carl Zeiss, Inc.) with EC Plan-Neofluar 179 
×40 NA 0.75 lens.  Antibodies are listed in Table S6. 180 
Deep Sequencing of B Cell IgH CDR3 region  181 
Peripheral blood B cells (>60,000) from 83C/291Q, K108E and three age-matched 182 
controls were FACS sorted to >95% purity and genomic DNA extracted using standard 183 
methods.  High throughput sequencing of the B cell receptor heavy chain (IgH) CDR3 184 
region was undertaken using Adaptive Biotechnologies® immunoSEQ Assay 185 
(www.adaptivebiotech.com).  Further details are available in Supplementary Materials.  186 
Statistical analysis 187 
Graphs were plotted with Prism V5 (GraphPad software Inc) and mean, standard 188 
deviation, z scores and student’s t-tests were calculated within the software.  For GO 189 
ontology analysis (Figs 4E, 5E-G) and BCR IgH gene usage (Fig 7D), R version 3.3.0 190 
was used, together with ‘bimaRt’ and ‘GOstats’ and ‘ggplot2’ packages. 191 
  192 
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Results  193 
Immunodeficiency 194 
A caucasian male, born to non-consanguineous parents, had an early history of 195 
recurrent, severe viral respiratory tract infection with influenza H1N1, rhinovirus and 196 
mycoplasma, often requiring hospitalization and ventilatory support (Figure 1A; see 197 
Supplementary Information for full details).  Developmental delay had been noted 198 
and multifocal bilateral calcification was present at 3yrs (Figure 1B).  Total CD4+, CD8+ 199 
T cells, B and NK cells were normal and T cell PHA responses were intact (Table S1).  200 
IgA deficiency was noted during infancy (Table S2).  Whole blood cytokine assay 201 
revealed absent IL-12 production with reduced IFNγ, IL-6, IL-10 and TNFα in response 202 
to BCG, LPS or LPS and IFNγ (Figure 1C).  No anti-nuclear antibodies were identified 203 
in serum by Bioplex 2200 screening, but analysis across a human protein microarray 204 
(HuProt™), representing more than 15,000 genes, revealed a striking reactivity against 205 
immunoglobulin heavy and kappa and lambda light chains compared to two age 206 
matched controls (Figure 1D).  A number of discrete non-immunoglobulin targeted 207 
antibodies were identified in the patient and a smaller number in controls (Figure 1E). 208 
Compound heterozygous IRF8 mutations: R83C and R291Q  209 
Whole exome sequencing of the patient and both parents identified two novel missense 210 
mutations in coding regions of IRF8: c.247C>T; p.Arg83Cys and c.872G>A; 211 
p.Arg291Gln (Figure 2A).  Four genes with bi-allelic variants were identified.  Of these, 212 
IRF8 had the highest CADD scores and was most biologically plausible (Table S3).  213 
Both IRF8 mutations were absent from ExAC, dbSNP147, EVS, NHLBI GO Exome 214 
sequencing project, gnomAD databases and 116 locally sequenced samples.  The 215 
mutated residues were highly conserved between IRF family members and IRF8 216 
orthologs (Figure 2B). 217 
 218 
In luciferase reporter assays both R83C and R291Q failed to activate a derivative of the 219 
PSMB8 promoter EICE in the presence of PU.1 or SPIB and were unable to repress 220 
IRF1-mediated expression through the TAPASIN promoter ISRE (Figure 2C).  221 
However, a difference was observed in reporter constructs containing the IL-10 AICE 222 
activated by BATF/JUNB.  This element is repressed by wild-type IRF8.  Here the R83C 223 
variant was inactive but R291Q was comparable with wild type.  These results were 224 
consistent with binding patterns seen in EMSA, where only wild-type IRF8 bound to 225 
DNA in the presence of the appropriate co-factor except for the AICE probe which 226 
retained R291Q binding of in the presence of BATF/JUNB (Figure 2D).  Total IRF8 227 
protein expression was normal in patient lymphoblastoid cell lines and whole cell lysates 228 
of transfected HeLa cells (Figure 2E,F) but, in cellular fractionation experiments, R83C 229 
was unable to translocate to the nucleus (Figure 2G). R291Q showed a nuclear-230 
cytoplasmic distribution similar to wild-type protein. 231 
 232 
Monocyte and dendritic cell deficiency with preserved tissue macrophages 233 
Accurate monocyte and DC profiling was possible only after exclusion of abundant 234 
CD15+ granulocytes in the PBMC fraction (Figure 3A).  This revealed a profound 235 
depletion of CD14+ classical monocytes, CD16+ non-classical monocytes, CD123+ 236 
plasmacytoid DCs, CD141+ cDC1 and CD1c+ cDC2 (Figure 3A-C; Figure S1).  As 237 
recently reported, there was a relative excess of CD56bright immature and depletion of 238 
CD56dim mature NK cells (Figure S1D).  In the dermis, CD14+ monocyte-macrophages, 239 
CD141+ cDC1s and CD1c+ cDC2s were similarly decreased, while lymphocytes and 240 
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auto-fluorescent dermal resident macrophages were preserved.  Elective 241 
bronchoalveolar lavage (BAL) was also depleted of DCs, CD14+ and CD16+ monocyte-242 
derived cells but SSChiCD45hiCD206+ alveolar macrophages and SSClowHLA-DR- 243 
lymphocytes remained in normal numbers.  BAL CD15+ granulocytes were 244 
approximately 10-fold more abundant than controls (Figure 3C).  Proliferating epidermal 245 
Langerhans cells were also intact (Figure 3D).  BAL cytokines were also grossly 246 
disturbed (Figure S2A). 247 
Dysregulation of granulopoiesis  248 
Myeloproliferation consisted of abundant, hypogranular neutrophils with reduced 249 
density, low light side-scatter properties and reduced mRNA expression of a number of 250 
primary and secondary granule components (Figure 3A, Figure S2B).  CD34+ 251 
progenitors, including CD38loCD45RA-CD90+ HSCs, were consistently mobilized into 252 
the PB (Figure 4A).  Myelopoietins were increased in serum, including the products of 253 
several IRF8-bound genes (IL1RA, PDGFB, CCL4, CCL5, IL1B, IL10) and expression 254 
of cathepsin G (CTSG) was increased (Figure 4B,C).  The neutrophil oxidative 255 
respiratory burst, tested in the absence of corticosteroid therapy, was reduced in 256 
frequency in response to E.coli and reduced in intensity (MFI) in response to both E.coli 257 
and PMA (Figure 4D).  The patient was also basopenic (Figure 4E).  Many transcripts 258 
expressed in neutrophils were differentially regulated compared with healthy controls, 259 
including a number of interferon-regulated and IRF8-bound genes (Figure 4F, Tables 260 
S5,S6).  261 
Dysregulation of lymphoid gene expression 262 
A total of 125 transcripts were differentially regulated in sorted lymphoid cells (73 up- 263 
and 54 down-regulated; (Figure S3A).  A core set of 11 genes varied in expression in 264 
all lineages.  These included up-regulation of the anti-bacterial protein lactoferrin, NFIL3 265 
and CCR1 and down-regulation of TNFAIP3, CCL3, CCL4, HLA-DRA, CXCR4, IRF1, 266 
CDKN1A and DUSP4.  More than half of all differentially expressed genes showed 267 
interferon-dependent transcription and approximately a third (45/125) were IRF8 bound 268 
according to homology mapping of ChIP-seq data in the mouse4.  Within the NanoString 269 
codeset, a number of pathways were significantly differentially regulated (Figure S3B, 270 
Table S5).  The NanoString panel contained 82 of the DEGs identified by RNA-Seq in 271 
the K108E patient.  Of these, 36 were differentially expressed by both patients and 15 272 
were IRF8 bound (Table S6). 273 
Impairment of CD8+ memory differentiation and Th1/Th17 polarization 274 
T cell numbers (CD4+, CD8+ and Treg) and PHA responses were normal (Figure 275 
S4A,B).  CD4 memory differentiation was normal (Figure S4C) but CD8+CD45RA-276 
CD27- effector memory cells were reduced in number in blood and BAL (Figure 5A,B, 277 
S4D)37.  Th1 and Th17 differentiation was impaired and Th2 differentiation increased, 278 
by cytokine secretion and intracellular staining (Figure 5C,D).  Production of GM-CSF 279 
by CD4+ and CD8+ T cells was increased (Figure 5C) but CD8+ T cells also produced 280 
significantly less IFNγ (Figure 5D).  T-BET and STAT1 expression were also decreased 281 
in bulk sorted T cells (Figure 5D).  CXCR3 was virtually undetectable (<2% expression) 282 
on CD4+ T cells, CD8+ T cells and Tregs isolated from the blood and BAL of the patient 283 
(Figure 5E, S4E). 284 
Impaired B cell maturation and BCR diversification 285 
Although CD38+CD27- transitional B cells and CD38hiCD27+ plasmablasts were normal, 286 
both IgD+CD27+ and IgD-CD27+ memory cells were reduced (Figure 6A, B).  Total IgG, 287 
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IgM and IgE were normal but IgA and IgG2 were reduced (Figure 6C).  Although the 288 
patient mounted normal specific IgG responses to childhood vaccines, antibodies to HiB 289 
and pneumococcus were not durable and fell to non-protective levels by the age of 290 
three (Table S2).  Deep sequencing of the immunoglobulin heavy chain (IgH) 291 
complementarity-determining region 3 (CDR3) was performed on B cell DNA isolated 292 
from both R83C/R291Q and K108E/K108E patients.  Clonality and successful template 293 
rearrangement were normal (Figure S5A,B) but CDR3 length was shorter in both 294 
productive and non-productive templates of the patients (Figure 6D, Figure S5C,D), 295 
consistent with reduced numbers of non-templated N1 and N2 nucleotide insertions 296 
(Figure 6E).  Both patients had proportionally fewer productive templates that had 297 
undergone somatic hypermutation (Figure 6F) and a truncated distribution of SHM 298 
counts with fewer mutated bases per template (Figure 6G).  A survey of VH gene 299 
expression identified restricted gene usage compared to age matched controls (Figure 300 
6H).   301 
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Discussion 302 
 303 
This report describes the hematological defects and immune dysregulation due to 304 
compound heterozygosity of two new defective IRF8 alleles, R83C and R291Q, the 305 
latter orthologous to R294C, a hypomorphic mutation responsible for the BXH2 mouse 306 
phenotype.  Similarly to the previously reported child carrying IRF8K108E/K108E, the 307 
patient, who was studied in the absence of active infection, had granulo-proliferation 308 
with profound DC and monocyte deficiency.  Further analysis revealed dysregulation of 309 
B, NK and T cells.  Although it cannot be proven that lymphoid defects are due to 310 
intrinsic loss of IRF8, a number of findings accord with known direct effects of IRF8.   311 
These observations shed new light on the mechanisms of immunodeficiency in bi-allelic 312 
IRF8 mutation which now include maturation and functional deficits of NK cells, 313 
deficiency of Th1, Th17 and CD8 effector memory responses and blunted somatic 314 
hypermutation, class-switching and memory B cell formation. 315 
 316 
At the phenotypic level, analysis of this compound heterozygous patient suggests that 317 
susceptibility to viral infection, myeloproliferation and developmental delay associated 318 
with cerebral calcification are consistent features of bi-allelic IRF8 mutation, as they 319 
were similarly seen in homozyogous K108E mutation31.  The previous case also 320 
indicates high susceptibility to mycobacterial infection.  Although the compound 321 
heterozygous patient was less critically ill, having not been exposed to BCG vaccine in 322 
infancy, immunodeficiency was severe enough to warrant hematopoietic stem cell 323 
transplantation at age 4yrs.  324 
 325 
The novel IRF8 variants, affecting conserved residues, were functionally defective in 326 
vitro.  R83, in the DBD of the protein, forms hydrogen bonds with the guanine of the 327 
GAAA core IFN-stimulated response element (ISRE)38, 39.  R83 belongs to one of the 328 
two basic residue clusters which form the bipartite nuclear localization signal of IRF840, 329 
explaining the defective nuclear translocation of R83C in cellular localization assays, a 330 
feature shared with K108E mutant protein32.  R291 is one of only twelve invariant 331 
residues in the IADs of IRFs.  Crystal structures of IRF3 and IRF5 show that this 332 
residue, lying between helix 2 and helix 3, directly interacts with Ets factor and IRF 333 
partners in the formation of DNA-binding dimers41.  Mutation of the orthologous murine 334 
residue 294 in the BXH2 mouse, blocks the function of IRF8 in complementation assays 335 
and affects the ability of IRF8 to interact with other TFs through the IAD42.  Luciferase 336 
reporter assays and EMSA showed that both variants were unable to activate EICE with 337 
PU.1 or SPIB and were unable to compete with IRF1 at the ISRE.  R83C was unable to 338 
bind with BATF/JUN at the AICE but R291Q maintained activity.  Although this suggests 339 
that R291Q might function effectively as a partner of BATF to facilitate the terminal 340 
stages of cDC1 development21, this cannot be interrogated since the failure to co-341 
activate SPI1/PU.1 directed genes blocks DC and monocyte development at an earlier 342 
stage.  Taken together, the molecular characteristics of the mutations and the 343 
phenotypic similarities with the patient carrying null K108E mutations suggest that 344 
compound heterozygous R83C and R291Q mutations result in IRF8 activity below the 345 
threshold for function. As IRF8 contains a super-enhancer region, gene dosage is likely 346 
to be critical for normal function. 347 
 348 
The mechanism of granulo-proliferation in IRF8 deficiency may be multifactorial with 349 
increased production and mobilization but reduced apoptosis of progenitors and 350 
neutrophils.  Firstly, through co-operation with PU.1 and inhibition of CEBPA at the 351 
molecular level, IRF8 is responsible for the balanced generation of myeloid cells in the 352 
GMP compartment43.  Spontaneous granulo-proliferation, owing to the unopposed 353 
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action of CEBPA, is a consistent finding in both patients with bi-allelic IRF8 mutation, 354 
BXH2 and Irf8-/- mouse models. Secondly, it was observed that myeloid progenitors, 355 
including hematopoietic stem cells, were mobilized into the blood.  CXCL12/CXCR4-356 
mediated retention in the bone marrow may have been attenuated owing to increased 357 
expression of cathepsin G, which degrades CXCL12, and reduced expression of 358 
CXCR4, an IRF8 target gene44, 45.  Growth factors known to mobilize progenitors, 359 
including SCF46, HGF47 and VEGF48, were also increased.  Finally, Irf8-/- progenitors are 360 
hyper-responsive to G-CSF49 and defective in their inability to upregulate BAX and 361 
FASL-mediated apoptosis during the termination of emergency myelopoiesis50,51. In 362 
keeping with this, apoptosis-related genes were down-regulated in patient neutrophils.   363 
The expanded neutrophil population was comprised of cells reminiscent of those seen 364 
in myelodysplasia; hypogranular with low light side-scatter properties52, defects in 365 
primary and secondary granules53 and defective respiratory burst responses54. 366 
Excessive granulopoiesis appeared to contribute to respiratory complications.  At rest, 367 
the BAL contained high numbers of granulocytes associated with elevated inflammatory 368 
cytokines and chemokines including TNFα, IL-8, CCL2, CCL3 CXCL12, IL-6 and IL-1β.  369 
During respiratory infection, treatment with glucocorticoids exacerbated the neutrophil 370 
response often leading to a clinical deterioration, whereas treatment with DNAse was 371 
effective, consistent with the lysis of excessive extracellular neutrophil DNA55. In 372 
contrast to the neutrophils, basophils were reduced, in keeping with a known function of 373 
IRF856. 374 
 375 
A much broader cytopenia, encompassing all monocytes and DCs, was seen in both bi-376 
allelic humans compared with the full Irf8 knockout mouse which still retains some 377 
monocytes and pDCs and has intact cDC2s20.  The homozygous R294C BXH2 mouse 378 
and heterozygous Irf8 knockout mouse, are only deficient in cDC1s which require IRF8 379 
for terminal differentiation20.  Such selective defects have not yet been observed in 380 
humans.  However, other alleles of IRF8 have been described that do not impair DC 381 
and monocyte development to the same degree.  Notably, the heterozygous T80A 382 
mutation, although described as a dominant negative in reporter assays, had a very 383 
modest effect on DC development with apparent loss of cDC231. This pattern is 384 
unexpected based on the mouse models in which cDC2 are always preserved, but the 385 
appearance of atypical CD11c+CD1c- cells in the human suggests that T80A disturbs 386 
hematopoiesis by an allele-specific mechanism that has not yet been elucidated.  387 
Additional IRF8 variants recently described by Mace et al.25 also showed more subtle 388 
deficiency of monocytes and DCs but pronounced effects upon NK cell development. 389 
These variants were localized to the IAD (P224L and A201V).  Neither allele was 390 
compromised in reporter assays using the EICE with PU.1 or SPIB or the ISRE with 391 
IRF1, suggesting that the loss of protein-protein interactions was responsible for 392 
lineage-restricted functional deficits.  It is highly likely that other IRF8 variants will come 393 
to light with allele-specific effects upon hematopoiesis and immunity.  Precise inter-394 
species mapping may not always be possible owing to the complexity of interactions 395 
between IRF8, IRF4 and other TFs.  396 
 397 
The preservation of LCs and macrophages in states of severe monocytopenia, such as 398 
GATA2 and IRF8 deficiency, remains a key demonstration of the ability of human tissue 399 
macrophages to survive without continual replenishment by monocytes31, 57.  These 400 
observations were extended to the alveolar space, which contained large numbers of 401 
macrophages.  At least partial preservation of macrophages and LCs is seen in the 402 
BXH2 and Irf8-/- mouse models58, 59 although functional deficits are apparent4, 12, 60. The 403 
contribution of macrophage dysfunction to the human phenotype of IRF8 deficiency 404 
remains to be determined, in particular, whether the developmental delay and 405 
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intracerebral calcification seen in patients bearing IRF8K108E/K108E and IRF8R83C/R291Q are 406 
related to the reported role of Irf8 in murine microglial development and function61, 62.  407 
There was no evidence for disordered calcium metabolism but we cannot exclude 408 
infectious complications or dysregulated interferon signaling as contributors to this 409 
phenotype.  410 
 411 
Lymphocyte development and function in IRF8 deficiency may be altered through both 412 
direct cell-intrinsic effects and indirect effects due to defective hematopoiesis and 413 
external influences such as infection.  Analysis of the lymphoid compartment showed 414 
transcriptomic dysregulation with phenotypic and functional defects in NK, T and B cells.  415 
 416 
Transcriptome analysis of purified lymphocyte populations revealed enrichment within 417 
up-regulated genes for response to pathogen pathways (LTF, CXCL1, CD27, TNFRSF) 418 
and immune response (NFIL3, CCR1), with down-regulated genes involved in cytokine 419 
signaling (including IFNγ), cytokine production (CCL3, CCL4), TLR signaling (including 420 
TLR3, 4, 5), cell activation (HLA-DR) and regulation of cell cycle and apoptosis 421 
(DUSP4, CDKN1A).  Aberrations in TNF signaling were apparent with up-regulation of 422 
both TNF and TNFR superfamily members but universal down-regulation of IRF8-bound 423 
TNF-induced TNFAIP3, a negative regulator of cytokine-mediated immune and 424 
inflammatory responses.  IRF1 was also reduced, further contributing to loss of gene 425 
expression governed by the IRF8/IRF1 regulome4.   426 
 427 
Defects in NK cell maturation and function were recently reported as an example of 428 
more widespread immune dysregulation due to IRF8 mutation, using data from the 429 
IRF8K108E/K108E and IRF8R83C/R291Q patients.  Both show an increased proportion of 430 
immature CD56bright NK cells, suggesting impaired NK maturation.  Defective NK-431 
mediated cytotoxicity was also reported in a patient with mutations in the IAD region 432 
(201V/224L) who had severe EBV infection without significant DC or monocyte 433 
deficiency25.   434 
 435 
In the T cell lineage, profound defects in Th1, Th17 and CD8 effector memory 436 
development were observed, together with almost complete absence of CXCR3, the 437 
chemokine receptor for CXCL9,10,11 that plays a vital role in the positioning of 438 
activated T cells in tissues63.  IRF8 is up-regulated during T cell activation28 and 439 
experiments with Irf8-/- antigen-specific T cells indicate a number of cell-intrinsic 440 
regulatory roles for IRF8 including the integration of γ-chain cytokine and TCR signaling 441 
pathways, secretion of IFNγ and cytotoxicity26.  IRF8 also regulates STAT1 through 442 
mutual promoter binding64,65 and represses the GM-CSF gene in T cells66.  In Itgax 443 
(CD11c) conditional Irf8 knockouts, T cell dysfunction was proposed to be largely 444 
extrinsic through the loss of cDC1, although recombination was also observed in 445 
lymphoid cells, which express CD11c when activated67.  Evidence for an intrinsic role of 446 
IRF8 in Th17 differentiation is conflicting67.  It is likely that the strength of TCR signaling 447 
is significantly compromised both by the lack of DCs and intrinsic defects including 448 
attenuated STAT1-mediated signaling, especially critical for γIFN-driven Th1 449 
differentiation.  Both potentially contribute to the failure of Th1, Th17 and CD8 effector 450 
memory differentiation and lack of CXCR3 expression, leading to compromised 451 
peripheral tissue T cell homeostasis.  Transcriptome analysis of purified T cells showed 452 
global down-regulation of pathways involved in cell signaling, cytokine production and 453 
cell activation, consistent with gene expression analysis of whole PBMC by RNA-Seq in 454 
IRF8K108E/108E patient32. 455 
 456 
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In B cells, lineage-specific knockout in mouse indicates that Irf8 is required at several 457 
stages of B cell development including the maintenance of central tolerance in the BM, 458 
differentiation of follicular B cells, germinal center formation, antibody affinity maturation 459 
and memory cell formation7,23.  Correlates of these intrinsic effects were observed in 460 
human. In both IRF8R83C/R291Q and IRF8K108E/K108E patients, the extent and complexity of 461 
SHM was reduced, a factor directly associated with serious respiratory infection in 462 
patients with CVID68.  Comparison of CDR3 sequences between both patients and age-463 
matched controls showed shorter lengths with fewer N1 and N2 insertions.  Although 464 
terminal deoxynucleotidyl tranasferase (TdT), responsible for N insertions, is not known 465 
to be a direct target of IRF8, impairment is seen in other conditions with perturbed 466 
hematopoiesis and aberrant B cell development69.  Restricted VH gene repertoire may 467 
also reflect abnormal V(D)J recombination within the BM70 or represent defective 468 
secondary receptor editing71.  Although shorter in-frame CDR3 regions were 469 
appropriately selected for compared to out-of-frame sequences, suggesting intact 470 
central B cell tolerance72, the presence of widespread anti-immunoglobulin reactivity 471 
across a human proteome microarray was striking in the serum of the patient carrying 472 
IRF8R83C/R291Q compared to age-matched controls.  The clinical significance of auto-473 
reactive antibodies in this age group is uncertain but, in the absence of autoimmune 474 
clinical symptoms, the anti-Ig activity may represent an appropriate response to 475 
recurrent infections73.  Recent data indicate that IgA deficiency may be explained by a 476 
lack of DC-B cell interaction in the Peyer’s patches74.  477 
 478 
In summary, this report defines two new variants of IRF8 associated with defective 479 
function in a compound heterozygous patient.  Profound cytopenia of DCs and 480 
monocytes in the context of granulo-prolfieration, were confirmed as a consistent 481 
features of immunodeficiency compounded by intrinsic and extrinsic dysregulation of 482 
lymphoid cell development, maturation and responses.  These observations are broadly 483 
consistent with the notion that IRF8 controls a set of multi-lineage functions that hone 484 
protective immunity to viral infection and intracellular pathogens.  These range from 485 
governing the hematopoietic development of cross-presenting cDC1s, interferon-486 
producing pDCs and monocytes to the fine-tuning of NK maturation, Th1, Th17 487 
polarization, effector memory development and durable production of high-affinity class-488 
switched antibody.  This is achieved through multi-level and multi-lineage control of 489 
gene expression, the failure of which is mirrored by a complex syndrome of 490 
immunodeficiency. 491 
  492 
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Figures and Legends 511 
Figure 1: Immunodeficiency 512 
 (A) Clinical course of the patient showing PB neutrophil count (x109/l) compared to the 513 
upper limit of normal.  Black dots represent hospital admissions, boxes indicate 514 
pathogens isolated, outlined boxes indicate admission to intensive care for respiratory 515 
support and length of stay. 516 
(B) Standard non-contrast enhanced CT showing multifocal bilateral parenchymal 517 
calcification (white arrows), involving the subcortical white matter, globus pallidi, internal 518 
capsule and dentate nuclei. 519 
(C) Whole blood cytokine production from the patient bearing IRF8R83C/R291Q (black) 520 
compared to a travel control (gray). 521 
(D-E) Antibody reactivity in the serum of the subject patient and two age-matched 522 
controls against a panel of protein targets representing greater than 15,000 human 523 
genes (HuProt™). (D) anti-immunoglobulin heavy chain (IGH) or light chain (IGK and 524 
IGL) reactivity after quantile normalization across the three samples and (E) non-525 
immunoglobulin antigen reactivity present discretely in the patient or controls. 526 
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Figure 2: Compound heterozygous IRF8 mutations R83C and R291Q 528 
(A) IRF8 genotype of the proband (III.1) and family. 529 
(B) Protein schematic and multiple sequence alignment of IRF8 orthologs. Mutated 530 
amino acids and core ISRE binding residues are marked. 531 
(C) Evaluation of IRF8/co-factor transcriptional potential as determined by relative 532 
luciferase activity of IRF response elements in the absence of IRF8 (‘none’) or 533 
transactivated by wild type IRF8 or variants R83C and R291Q, in the presence of PU.1 534 
and PSMB8 derivative (EICE); SPIB and PSMB8 derivative (EICE); IRF1 and TAPASIN 535 
(ISRE); BATF/JUNB and IL10 (AICE) as indicated.  Graphs show results from n=3 536 
experiments.  Luciferase activity is displayed relative to cells co-transfected with empty 537 
vector, normalized to ‘1’.  Data were analyzed using an unpaired t-test (** P < 0.01, *** 538 
P < 0.001). 539 
(D) Evaluation of IRF8/co-factor complex-forming potential as determined by 540 
electrophoretic mobility shift assays (EMSA) using nuclear extracts prepared from HeLa 541 
cells transfected with IRF8 WT or variants, R83C and R291Q, and mixed with extracts 542 
containing PU.1 and PSMB8 derivative (EICE); SPIB and PSMB8 (EICE); IRF1 and 543 
TAPASIN (ISRE); BATF/JUNB and IL10 (AICE) as indicated. Arrows indicate IRF8/co-544 
factor complexes. 545 
(E) Flow cytometric evaluation of intracellular IRF8 protein expression in EBV-546 
transformed B cells (LCLs) from the subject patient and two controls. 547 
(F) IRF8 expression in whole cell lysates from HeLa cells transfected with the indicated 548 
constructs. 549 
(G) IRF8 and TUBULIN expression in cytoplasmic ‘C’ and nuclear ‘N’ fractions of HeLa 550 
cells transfected with the indicated constructs.  Transfected IRF8 was detected using 551 
both anti-IRF8 and anti-HA 552 
  553 
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Figure 3: Monocyte and DC deficiency with preservation of macrophages and LCs  555 
(A) Flow cytometric analysis of PBMC showing CD15-SSClow lymphocytes, CD15-556 
SSCmed monocytes and residual CD15+ granulocytes with morphology confirmed by 557 
Giemsa staining.  Pie charts represent proportions of cells in PBMC of the patient 558 
(83C/291Q) and the mean of controls (n=9). 559 
(B) Flow cytometric PBMC profiling of the patient and a control after staining with anti-560 
CD15 to exclude abundant, hypogranular neutrophils with high non-specific antibody 561 
binding.  Lineage (CD3, 19, 20, 56)-HLA-DR+ gate contains CD14+ classical monocytes 562 
(Gate 1), CD14-CD16+ non-classical monocytes (2), CD123+ pDC (3) and CD34+ 563 
progenitors (4), CD141+ cDC1 (5) and CD11c+CD1c+ cDC2 (6). 564 
(C) Flow cytometry profiling of blood, dermis and BAL.  Absolute counts (BD 565 
TruCount™) in whole blood.  Lymphocytes were gated as CD3+ T cells, CD19+ B cells 566 
and CD3-CD56+ NK cells.  Bars represent mean +/- SD of 18 controls.  Dermis bars 567 
represent mean +/-range of 3 healthy controls.  BAL bars represent mean +/- range of 4 568 
healthy controls 569 
(D) Enumeration of LCs by immunofluorescence microscopy of an epidermal sheet from 570 
the patient stained with anti-CD1a, anti-Ki-67 and DAPI.  Numbers of LCs and Ki-67+ 571 
proportions derived from the mean of 6 fields of view (at x20 or x40 magnification) for 572 
the patient and n=13 or n=3 healthy controls, respectively. Bars represent mean +/- SD.  573 
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Figure 4: Dysregulated granulopoiesis  576 
(A) Flow cytometric analysis of CD34+ progenitors in PBMC from a control and patient 577 
(83C/291Q).  Lineage-CD34+ cells contain; CD38+CD10+ BNK precursors (Gate 1), 578 
CD10-CD45RA- common myeloid progenitor/megakaryocyte-erythroid progenitor 579 
(CMP/MEP, 2) and CD45RA+ granulocyte-macrophage progenitor (GMP, 3).  CD38- 580 
cells contain CD45RA+ lymphoid-primed multi-potent progenitors (LMPP, 4), CD45RA-581 
CD90- multi-potent progenitors (MPP, 5) and CD90+ Hematopoietic Stem Cells (HSC, 582 
6).  Numbers represent the percentage of cells in the upstream gate or (percent of 583 
CD34+ cells). 584 
(B) Serum cytokine analysis by Luminex™ in 83C/291Q (black) compared to n=10 585 
controls (gray).  Graph shows cytokines outside the reference range (z-score ≥2).  586 
Cytokine genes with IRF8 binding site within 20kb of the transcription start site indicated 587 
by +. 588 
(C) Cathepsin G (CTSG) expression in neutrophils from 83C/291Q and n=3 controls, 589 
analyzed by NanoString Human Immunology V2 panel (controls gray; 83C/291Q black). 590 
(D) Dihydrorhodamine oxidative burst response of whole blood neutrophils to PBS, E. 591 
coli and Phorbol 12-myristate 13-acetate (PMA).  83C/291Q is shown in black.  Gray 592 
bars indicated the mean +/- SD of 45 controls. 593 
(E) Basophils identified as lineage-HLA-DR-CD45lowCD123+.  Absolute count (BD 594 
TruCount™) in whole blood. Bars represent mean +/- SD of 18 controls. 595 
(F) Heat map showing differential gene expression ≥1.5 log2 from control mean and z 596 
score ≥2 between 83C/291Q and controls (n=3).  Open circles: genes differentially 597 
regulated by interferon; filled squares: genes bound by IRF8.  Pie charts: Gene ontology 598 
(GO) terms significantly (p<0.01) enriched after hyper-geometric testing of differentially 599 
regulated transcripts using the nCounter Human Immunology V2 panel as the gene 600 
universe.  601 
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Figure 5: Impairment of Th1/Th17 and CD8+ effector memory T cell differentiation. 604 
(A) CD4 and CD8 T cell differentiation defined by expression of CD27 and CD45RA and 605 
the proportions of each quadrant of CD8+ T cells (outlined gray circle) relative to 3 age-606 
matched controls (gray triangles) and published normal ranges75 (black bars), analyzed 607 
as a percentage of total CD8+ T cells. 608 
(B) Proportion of CD27-CD45RA- CD8+ T cells in the PB of the patient (black) versus 609 
controls (gray) and BAL of the patient (black) versus published mean of normal controls 610 
(star).  611 
(C) Cytokine secretion into culture medium, as determined by Luminex™ by purified 612 
CD4+ and CD8+ T cells from the patient and n=4 healthy controls following 613 
PMA/ionomycin stimulation.  Bars represent mean +/-95%CI. 614 
(D) Intracellular cytokine production by purified CD4+ and CD8+ T cells from the patient 615 
and n=4 healthy controls following PMA/ionomycin stimulation and selected gene 616 
expression analysis in 83C/291Q (black) versus n=5 age-matched controls, determined 617 
by NanoString nCounter technology (Human Immunology V2 panel).  Bars represent 618 
mean +/-95%CI. 619 
(E) Flow cytometric analysis of CXCR3 expression on CD4+, CD8+ and CD4+CD127-620 
CD25+ regulatory T cells from representative control and patient with the percentage of 621 
CXCR3+ cells indicated.  Summary of CXCR3 expression in 83C/291Q blood (filled) and 622 
BAL (open) CD4+, CD8+ and CD4+CD127-CD25+ regulatory T cell subsets vs 6 healthy 623 
controls (gray). Bars represent mean +/-95%CI. 624 
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Figure 6: Reduced memory B cells with impaired somatic hypermutation 628 
(A) Flow cytometric analysis of B cell phenotype in 83C/291Q compared to an age-629 
matched control.  The left column shows populations defined by IgD and CD27: naïve 630 
(Gate 1), non-switched memory (2), switched memory (3), CD27-memory (4).  The right 631 
column shows populations defined by CD38 and CD27 to identify transitional (Gate 5), 632 
naïve-mature (6), mature-activated (7), memory (8) and plasmablastic cells (9). 633 
(B) PB B cell subsets, defined by CD27 and IgD expression, as a proportion of total B 634 
cells, from 83C/291Q (gray outlined dots) and three local age-matched controls (gray 635 
triangles) plotted against an age-specific (18months-4yrs) normal range 76).  Bars 636 
represent mean and range. 637 
(C) Serum immunoglobulin isotype levels (IgG, IgA, IgM and IgE) over time. Horizontal 638 
lines represent upper and lower limits of normal.  The right plot shows serum levels of 639 
IgG subtypes at age 6 months.  Gray bars show the reference range. (D-I) BCR IgH 640 
CDR3 region sequencing of genomic DNA from purified PB B cells (Adaptive 641 
Biotechnologies’ ImmunoSEQ Assay) from 83C/291Q (red), K108E  (blue) and 3 age-642 
matched controls (gray). 643 
(D) Summary of template generation showing the percentage of productive (Prod), out-644 
of-frame (OoF) or stop templates generated in 3 controls and 2 subjects. 645 
(E,F) Mean CDR3 length (E) (nucleotides) and (F) mean number of inserted 646 
untemplated nucleotides (N1 and N2) in out-of-frame and in-frame rearrangements from 647 
controls (C) and subjects (S).  648 
(G) Percent of templates with ≥1 mutated base. 649 
(H) Frequency of mutated bases per in-frame template, expressed as the percentage of 650 
total mutations. Bars represent mean and SD (E-H). Statistics were calculated using t-651 
test * p<0.05 ** p<0.01. 652 
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Supplementary Materials 
Clinical details 
A Caucasian male child, born at term, presented with respiratory distress at the age of 7 
weeks. He had an elevated total white cell count (59 x 109/l) with neutrophilia (49.5 x 109/l), 
a high C-reactive protein (122mg/l) and right mid-zone consolidation on chest radiograph. 
He improved with parenteral antibiotic treatment and influenza A virus (H1N1) was 
subsequently detected in respiratory secretions. Over the next 3 years he was admitted to 
hospital on 15 occasions for respiratory distress associated with wheeze and 
bronchospasm, and required intubation and ventilation 3 times. Rhinovirus was detected in 
respiratory secretions by PCR on 4 such occasions. With no evidence of sensitization to 
common aeroallergens and normal sweat test and videofluoroscopy, he was labeled as 
being severely asthmatic and treated accordingly. Unusually for asthma, however, he was 
refractory to corticosteroids and his condition rapidly deteriorated after treatment with 
prednisone more than once.  Intermittent high fevers, maculopapular rash, lassitude and 
limb pain were also observed, sometimes with HHV6 viremia. 
 
There was evidence of pulmonary consolidation on several occasions during acute 
presentations, but his subsequent CT chest showed full resolution of radiological changes. 
Examination of bronchoalveolar lavage fluid, at the ages of 1 and 3 years, revealed 
macrophages, neutrophils and bronchial epithelial cells but no evidence of proteinaceous or 
lipid deposits, or pathogenic organisms. At 12 months, the patient became unwell with 
measles-like illness following 1st dose of MMR. He developed a high fever 2-3 days after 
vaccination, followed by a maculo-papular rash 8-9 days later. He recovered spontaneously 
but did not receive a further dose of MMR. 
 
Clinical immunological investigations showed persistent neutrophilia, eosinophilia but 
basopenia, relatively normal hemoglobin and platelets. Intermittent monocytopenia was 
noted on automated blood counting. Lymphocyte subsets and proliferative T cells 
responses were normal and serum biochemistry was unremarkable (Table S1).  There was 
normal expression of CD18 and CD11 (a, b and c) on neutrophils. IgA deficiency in infancy 
improved over time.  Although there was initially a good response to immunization against S 
pneumoniae and H. influenza, specific antibodies had declined 2yrs after vaccination (Table 
S2). Anti-nuclear auto-antibodies were not detected by routine clinical screening. There was 
no family history of recurrent infections or immunodeficiency. 
 
Despite clinical recovery from respiratory infections his neutrophil count remained massively 
elevated, prompting further investigations to exclude hematological malignancy.  Bone 
marrow examination showed expanded granulopoiesis, with normal proportions of 
promyelocytes, myelocytes and neutrophils, normal megakaryocyte and red cell 
development, no increase in blasts and no evidence of dysplasia. Cytogenetic analysis was 
normal and there was no evidence of BCR-ABL or JAK2 mutation on molecular testing.  
 
During the course of his investigations delayed neurodevelopmental milestones were noted. 
He did not sit until age 10 months, walked at 30 months and he had abnormal fine motor 
skills. By the age of 3½ years he had not talked but had good receptive language and was 
able to make himself understood by non-verbal means. A CT scan of the head at age of 3 
years showed an unusual pattern of intracranial calcification with linear calcification of the 
internal capsule and white matter of the frontal and parietal lobes.  This finding was 
confirmed by MRI examination.  
Informed consent was taken for whole exome sequencing in an attempt to define the cause 
of this complex immunodeficiency disorder. This revealed compound heterozygous 
mutations in IRF8, as described below. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
In light of the severity of clinical symptoms, the theoretical risk of myeloid malignancy and 
the previous successful treatment of a female infant with IRF8K108E/K108E, the decision to 
treat with hematopoietic stem cell transplantation (HSCT) was taken. The patient was 
transferred to a UK center for children with primary immunodeficiency where, at the age of 
4yrs, he underwent a matched unrelated donor cord blood HSCT with treosulfan fludarabine 
and alemtuzumab with ciclosporine and mycophenolate mofetil and graft versus host 
disease prophylaxis. Engraftment was uneventful and there was complete reconstitution of 
all cell subsets without graft versus host disease associated with a dramatic improvement in 
clinical status, confirming a transplantable immune defect. At the time of writing, the patient 
remains clinically stable with partial donor chimerism. 
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Supplementary Methods 
Genetic analysis 
Genomic DNA was isolated from whole venous blood from the subject and parents by 
standard salt extraction, and enriched for exonic sequences by hybridization with Agilent 
SureSelect Human All Exon v5 Kit. Paired-end sequencing was performed on an Illumina 
HiSeq 2500 (100 bp reads) according to the manufacturers’ protocols. Whole-genome 
alignment to GRCh37 was performed with Novoalign (Novocraft Technologies). Alignments 
were processed in SAM/BAM formats (1 using Picard and the Genome Analysis Toolkit 
(GATK) 2, 3. Indel and single-nucleotide variants were called in gVCF format and combined 
with 116 other samples using the GenotypeGVCFs of the GATK followed by variant quality 
score recalibration according to GATK best practices.  Recalibrated variants were filtered 
according to a truth-sensitivity tranche threshold of 99.9%.  Variants with a minor allele 
frequency of ≥ 1% in dbSNP138, NHLBI GO Exome Sequencing Project database, or 
present in 116 locally sequenced samples were removed. The functional consequences of 
variation were determined with Ensembl’s Variant Effect Predictor4, Sift (http://sift.jcvi.org), 
Polyphen (http://genetics.bwh.harvard.edu/pph2) and Condel Consensus Deleteriousness 
score (http://bg.upf.edu/fannsdb/).  Variants were ranked according to Combined Annotation 
Dependent Depletion scores 5 (https://cadd.gs.washington.edu/score/).  
 
Under a recessive model of inheritance, whole exome sequencing identified <1% minor 
allele frequency biallelic variants in four genes: OR6N1, CSPG4, TTN and IRF8, (Table S3).  
OR6N1 encodes an olfactory receptor 6 and PRPH encodes a peripheral nerve cytoskeletal 
protein 7.  Neither is expressed in hematopoietic or immune cells (human protein atlas; 
www.proteinatlas.org).  IRF8 was identified as the likely candidate locus because the gene 
is appropriately expressed, the variants had the highest CADD scores (Table S3) and the 
patient was similar to previously described child with homozygous K108E mutations 8. 
Auto-antibody detection on human protein microarray 
Sera from the patient and two age-matched controls were incubated on HuProt™ human 
protein microarrays (CDI Laboratories, Baltimore, MD) at 1:1000 dilution, followed by 
probing with anti-human IgG(H+L)-Alexa546 (Invitrogen) antibodies. A negative control 
array was processed in parallel without addition of serum. Arrays were scanned on a LS400 
microarray scanner (Tecan), and fluorescence intensities of array spots determined by 
GenePixPro. Data from the negative control array was subtracted from serum array data, to 
correct for direct binding of the secondary reagent to immobilised proteins. The corrected 
fluorescence intensities were log2 transformed and quantile normalIPed for the three serum 
samples. 
Luciferase reporter constructs 
Luciferase reporter constructs containing promoter regions for human PSMB8 or TAPASIN 
have been described previously9. The EICE motif within the PSMB8 vector was modified by 
the substitution of the underlined C residues for G’s present in the wild-type sequence, 
GAGGAACTGAAACCG, for enhanced activation. The AICE motif was derived from an 
intronic region in the human IL10 locus (hg19 chr1: 206957777-2069580975) and cloned 
into the pGL2-Promoter vector (Promega). 
 
 
EMSA probe sequences 
The probes contained the following sequences with the relevant binding sites underlined 
(only one strand is shown): 
EICE motif (PSMB8 wild-type) (5’-CGGAGGAGGAAGTGAAAGCGAAAGCCACAGA-3’) 
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EICE motif (PSMB8 derivative) (5’-CGGAGGAGGAACTGAAACCGAAAGCCACAGA-3’) 
IRFE motif (TAPASIN) (5’-TTTGGAGGAAAGTGAAAGTGAAAGGAGGAAG-3’) 
AICE motif (IL10) (5’-GGTTGCAGTTTCGTTGTGAGTCAGGCCTGCT-3’) 
Transcriptomic analysis 
Freshly isolated peripheral blood B cells, NK cells and T cells were sorted into RLT buffer 
with 0.1% beta-mercaptoethanol at a concentration of 2,000 cells/µl and analyzed using 
nCounter® Human Immunology V2 panel. Normalization to positive and negative controls 
and to housekeeping genes was performed using nSolver™ Analysis Software and log2 
transformed for subsequent analysis. Genes differentially regulated by interferon were 
identified from Interferome v2.01 at www.interferome.org 10. IRF8-bound genes were 
identified using ChIP-Seq data from Gene Expression Omnibus (GEO) GSM2060952 11. 
Conversion from mouse to human orthologs was performed using HomoloGene 
(www.ncbi.nlm.nih.gov/homologene). IRF8 peaks unambiguously mapped to human 
orthologs were retained.  Mouse data were filtered to all peaks within 20kb of transcription 
start sites and compared against differentially expressed genes from the subject to identify 
those with ≥1 IRF8 peak. Significance was calculated using hypergeometric testing and p-
values corrected using the Benjamin Hochberg correction (false discovery rate 0.05). Heat 
maps were generated in Multi Experiment Viewer (MeV 4.8). To determine significantly 
(p<0.01) enriched Gene Ontology (GO) terms and pathways, a dataset of functional terms 
associated with each gene was constructed from the Ensembl database using ‘biomaRt’ 
package for ‘R’. Functional analysis was performed using ‘GOstats’ with the ‘universe’ set to 
all endogenous probes on the NanoString Immunology V2 panel. 
Deep sequencing of B cell IgH CDR3 region 
Peripheral blood B cells (>60,000) from 83C/291Q, K108E and three age-matched controls 
were FACS sorted to >95% purity and genomic DNA extracted using standard methods. 
High throughput sequencing of the B cell receptor heavy chain (IgH) CDR3 region was 
undertaken using Adaptive Biotechnologies® immunoSEQ Assay 
(www.adaptivebiotech.com).  PCR bias was controlled using a synthetic immune receptor 
repertoire 12. After read normalization, V, D and J gene segments, non-templated bases and 
bases that had undergone SHM were identified by comparison with all known V, D and J 
gene and allele members, according to the standard defined by the International 
ImMunoGeneTics (IMGT®) collaboration. Sequence- and sample-level analyses were 
performed using ImmunoSEQ Analyzer. Clonality was calculated within the program to 
provide a measure (0-1) of the shape of the frequency distribution of all productive clones in 
the sample (inverse of the normalized version of Shannon’s entropy4). No sample had a 
clone with frequency >0.036%. V region usage was displayed using the ggplot2 R package.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
Supplementary Figures and Tables 
Figure S1: Gating strategy for monocyte DC and NK analysis  
 (A) Gating strategy for Trucount analysis. CD3+ cells (Gate i) contain CD4+ (Gate 2) and 
CD8+ (Gate 3) T cell subsets. CD3-CD45lowCD34+ progenitors are identified (Gate 1) and 
the remaining CD3- cells are defined by expression of HLA-DR and CD4, including HLA-
DR+CD4- (Gate ii) CD19+ B cells (Gate 4), HLA-DR-CD4-CD123+ basophils (Gate 5) and 
CD123-CD45bri NK cells which can be further defined as CD16-CD56bright (Gate 6) or 
CD56dim (Gate 7). HLA-DR+CD4+ gate (iv) contains CD14+ classical (Gate 8) and CD16+ 
(Gate 9) non-classical monocytes, CD123+ pDCs (Gate 10), CD141+ cDC1 (Gate 11) and 
CD11c+CD1c+ cDC2 (Gate 12). 
(B) Flow cytometric analysis of dermis from subject and a representative control after 
collagenase digestion to single cell suspension. The CD45+ leukocyte population contained 
HLA-DR- (SSClow) lymphocytes (Gate 1), HLA-DR+ auto-fluorescent (AF+) macrophages 
(Gate 2), and in the HLA-DR+AF- gate, CD14+ monocyte-derived cells (Gate 3), CD14-
CD141+ cDC1 (Gate 4) and CD14-CD11c+CD1c+ cDC2 (Gate 5). 
(C) Flow cytometric analysis of leukocytes from density centrifugation of broncho-alveolar 
lavage (BAL) fluid. The CD45+SSClow gate contained HLA-DR-AF- or Lin+ lymphocytes (Gate 
1) and HLA-DR+ antigen presenting cells including CD14+ (Gate 2) and CD16+ (Gate 3) 
monocyte-derived cells, CD123+ pDC (Gate 4), CD141+ or BTLA+ cDC1 (Gate 5) and CD1c+ 
cDC2 (Gate 6). The CD45+SSChi gate contained HLA-DR+CD206+ alveolar macrophages 
(Gate 7) and CD15+CD45low granulocytes (Gate 8).  
(D) NK cell (CD45+HLA-DR-CD4-CD3-CD19-) phenotype by flow cytometric analysis in 
subject and a healthy control and percentage of CD56bright and CD56dim out of total NK cells 
in subject compared to n=20 controls.  
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Figure S2: Cytokine analysis of bronchoalveolar lavage fluid and gene 
expression of neutrophil granule components 
(A) Cytokine and chemokine profile of bronchoalveolar fluid measured by Luminex™ 
(human cytokine multiplex panels) in subject compared to n=4 healthy controls, expressed 
as pg/ml: IFNα concentration, IL-27, inflammatory cytokines, cytokines involved in 
homeostasis of neutrophils in tissue.  
(B) Gene expression analysis of granule components in neutrophils of the subject compared 
to n=3 healthy controls. 
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Figure S3: Gene Expression and ChIP-Seq Analysis 
(A) Heat maps showing differential gene expression in FACS sorted B, T and NK cells ≥1.5 
log2 from control mean and z score ≥2 between 83C/291Q and controls (n=5).  Open 
circles: genes differentially regulated by interferon; filled squares: genes bound by IRF8.   
(B) Pie charts: Gene ontology (GO) terms significantly (p<0.01) enriched after hyper-
geometric testing of  differentially regulated transcripts using the nCounter Human 
Immunology V2 panel as the gene universe. Abbreviations: LM, leukocyte migration; CS, 
complement signaling; A, apoptosis; TM, T cell migration; CC, cell cycle regulation; TNF, 
tumor necrosis factor; IFN, interferon; TLR, toll-like receptor. 
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Figure S4: Additional T cell data 
(A) Representative flow cytometry and proportion of CD4+ and CD8+  T cells in the patient 
(gray circle) compared with 3 age-matched controls (gray triangles) and published normal 
ranges (black bars) 13.  
(B) 3H (tritiated) thymidine incorporation by lymphocytes isolated from the patient (black 
bars) and a control (gray bars) in response to phytohemagglutinin (PHA). 
(C) CD4+ T cell memory differentiation assessed by CD45RA and CD27 expression 
(D)  T cell subsets in BAL of the patient compared with control assessed by CD45RA and 
CCR7 expression.  CD27 expression was not measured for control BAL samples so the 
patient was also assessed with CD45RA and CCR7 for comparison. 
(E) CD27 expression within the CD45RA-CCR7- subset of CD8+ BAL T cells was assessed 
for comparison with published normal ranges (Figure 4B) 
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Figure S5: Additional B cell data 
(A) Clonality of B cells from 3 controls and the two subjects. (A,B,D) age-matched controls 
C1-3 (gray) and patients with IRF8R83C/R291Q (red) and IRF8K108E/K108E (blue). 
(B)  Summary of template generation showing the percentage of productive (Prod), out of 
frame (OoF) or Stop templates generated in 3 controls and 2 subjects. 
(C) In-frame CDR3 template length expressed as % of the total productive template 
(D) Out-of-frame CDR3 template length expressed as % of total templates. 
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Table S1: Blood profile and age 4yrs 
Complete blood count, lymphocyte subsets and routine clinical biochemistry of the subject 
at age 4yrs. Abbreviations: Hb: hemoglobin; Plt: platelet; MCV: mean cell volume; WBC: 
white blood count; Neut: neutrophils; Lymph: lyphocytes; Monos: monocytes; Eos: 
eosinophils; Baso: basophils; Ur: urea; Cr: creatinine; CRP: C-reactive protein; Alb: albumin; 
Adj: adjusted; Phos: phosphate; bili: bilirubin; ALP: alkaline phosphatase; ALT: alanine 
transferase; GGT: gamma glutamyl transferase 
 
 
CBC   Biochemistry   
Hb (115-155) g/L 112 Na (133-146) mmol/L 138 
Plt (200-450) 10*9/L 243 K (3.5-5) mmol/L 4 
MCV (77-87) fL 74.8 Ur (2.5-6.5) mmol/L 5 
WBC (5.5-14.5) 10*6/L 43.3 Cr (0-42) mmol/L 19 
Neuts (1.5-8) 10*6/L 35.9 CRP (0-5) 5 
Lymphs (1.5-7) 10*6/L 4.33 Alb (30-50) g/L 37 
Monos (0.7-1.5) 10*6/L 0.87 Adj Ca (2.18-2.63) mol/L 2.28 
Eos (0.3-0.8) 10*6/L 2.17 Phos (0.9-1.8) mmol/L 1.33 
Baso (0-0.1) 10*6/L 0 Mg (0.7-1) mmol/L 0.95 
Lymphocytes cells/ml)   Bili (0-21) umol/L 3 
T cells (900-4500) 2058 ALP (150-375) U/L 151 
B cells (200-2100) 1225 ALT (0-40) U/L 9 
NK Cells (100-1000) 1458 GGT (0-70) U/L 12 
CD4+ T cells (500-2400) 1278   
CD8+ T cells (300-1600) 740   
CD4:CD8 ratio (0.9-2.9) 1.73   
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Table S2: Serum immunoglobulins and specific antibodies 
Serum immunoglobulin isotype concentrations and specific antibodies in the subject at 
given ages. Abbreviations: Hep, hepatitis; CMV, cytomegalovirus; EBV, Epstein-Barr virus; 
VCA, viral capsid antigen; HSV, herpes simplex virus; VZV, varicella zoster virus. 
 
 
Age 0.5yrs 0.75yrs 2yrs 3yrs 3.6yrs Ref range (g/l) 
IgG 4.9 4 10.4  11.4 3.0-9.0 
IgA <0.2 0.07 0.15  0.32 0.15-0.70 
IgM 0.69 0.73 1.2  1.46 0.4-1.60 
IgE 4  23.2   0.5-52 ku/l 
IgG1 4.11     2.3-5.8 
IgG2 0.41     0.3-3.9 
IgG3 0.44     0.10-0.80 
IgG4 <0.02     <0.50 
Tetanus  0.91  0.5  adequate >0.15 
Hib  3.85  0.07  adequate >1.0 
Pneumococcus  32.6  12  adequate >30 
Hep B IgG     Neg  
Hep C IgG     Neg  
CMV IgG     Neg  
EBV VCA IgG     Neg  
Measles IgG     Neg  
HSV IgG     Neg  
VZV IgG     Neg  
Toxoplasma IgG     Neg  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13 
Table S3: HuProt™ protein clones 
Clones of proteins used in the HuProt™ protein microarray analysis to determine serum 
auto-reactivity of subject and age-matched controls 
 
Name Clone Name Clone Name Clone Name Clone 
IGHG1 JHU08300.P087A06 IGK JHU05320.P056E07 KV205 JHU03021.P032B02 SIRPB1 JHU15174.P159B06 
IGHG1 JHU01487.P016B05 IGKC JHU15230.P160A07 KV205 JHU03021.P186H06 SNX33 JHU08338.P087A05 
IGHG1 JHU15996.P168D09 IGKC JHU08867.P093C02 IGKV (frag) JHU08869.P093A02 GNB3 
JHU07809.P082C0
5 
IGHG1 JHU01386.P015B05 IGKC JHU15228.P160C12 IGKV1OR2 JHU19024.P193G01 VDAC1 
JHU02868.P030C0
2 
IGHG1 JHU15225.P160A01 IGKC JHU16431.P173A07 IGL JHU15249.P160E12 TMEM116 
JHU01814.P019C0
2 
IGHG1 JHU15223.P160A12 IGKC JHU15137.P159A08 IGL JHU08200.P086C07 KJ900884 (frag) 
JHU07737.P081C1
0 
IGHG1 JHU07812.P082B07 IGKC JHU08868.P093C01 IGL JHU16434.P173A08 SCLT1 JHU15264.P160C07 
IGHG1 JHU02822.P030C03 IGKC JHU16293.P171B08 IGL JHU08870.P093F02 SPATC1 JHU16238.P170A06 
IGHG1 JHU06762.P071F01 IGKC JHU16433.P173C08 IGL JHU03695.P039F03 VRK2 JHU15471.P082B08 
IGHG1 JHU15226.P160C01 IGKC JHU16432.P173D07 IGL JHU08871.P093E02 MARCH2 
JHU01787.P019D0
4 
IGHG1 JHU15993.P168H02 IGKC JHU15231.P160C03 IGL JHU16435.P173D09 FN3K JHU14546.P153F11 
IGHG1 JHU16425.P173C09 IGKC JHU09354.P098A07 IGL JHU15134.P159C06 OTUD5 JHU15158.P159F11 
IGHG1 JHU15224.P160D07 IGKC JHU03585.P038A11 IGL JHU15135.P159C07 DNAJC11 JHU07801.P082A07 
IGHG1 JHU15997.P168F09 IGKC JHU15131.P159E07 IGL JHU16294.P171A06 GNA11 JHU15218.P160A02 
IGHG1 JHU15130.P159H12 IGKC JHU08866.P093B02 IGL JHU16000.P168G09 NUDT6 JHU00927.P010D03 
IGHG1 JHU16423.P173H04 IGKC JHU16098.P169H04 IGL JHU15328.P161D01 TSSK1B JHU00856.P009D08 
IGHG1 JHU15995.P168C09 IGKC JHU02036.P189D07 IGL JHU15329.P161G04 GDPD5 JHU01374.P015H04 
IGHG1 JHU15128.P159G06 IGKC JHU06466.P068C09 IGL JHU16436.P173E01 ELK2 (frag) JHU15432.P162B12 
IGHG1 JHU15994.P180G07 IGKC JHU16430.P173G06 IGL JHU08871.P093D02 SESTD1 JHU07568.P079B10 
IGHG1 JHU15994.P179G07 IGKC JHU15229.P160F12 IGL JHU15136.P159G07 IFI35 JHU00322.P004A07 
IGHG1 JHU08301.P087D10 IGKC JHU15227.P160G12 
  
SCAMP
2 JHU00364.P004B07 
IGHG1 JHU15327.P161B07 IGKC JHU15233.P160H03 
  
EIF3D JHU02720.P029E03 
IGHG1 JHU01874.P189D02 IGKC JHU15232.P160D03 
  
OCEL1 JHU08893.P093B01 
IGHG1 JHU06761.P071D01 IGKC JHU15132.P159H07 
  
APMAP JHU02415.P026C08 
IGHG1 JHU06646.P070H07 IGKC JHU15133.P159F07 
  
C17orf6
2 
JHU02511.P027D1
1 
IGHG1 JHU15129.P159F10 IGKC JHU02823.P030H07 
    
IGHG1 JHU00912.P010G07 IGKC JHU16098.P165A04 
    
IGHG1 JHU07813.P082E07 IGKC JHU02036.P022B05 
    
IGHG1 JHU01385.P015A12 
      
IGHG1 JHU16426.P173B01 
      
IGHG3 JHU08684.P091A07 
      
IGHG3 JHU15998.P168B09 
      
IGHG4 JHU03305.P035F12 
      
IGHV5-
78 JHU03793.P040F08       
IGHV7-
81 JHU14209.P149E04       
IGHD JHU15222.P160B12 
      
IGHD JHU00710.P008F07 
      
IGHA1 JHU16422.P173F01 
      
IGHA1 JHU15126.P159D07 
      
IGHA1 JHU16097.P169C08 
      
IGHA1 JHU05319.P056E09 
      
IGHA1 JHU04166.P044B02 
      
IGHA1 JHU09164.P096H06 
      
IGHA2 JHU15326.P161E03 
      
IGHA2 JHU16300.P171E11 
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Table S4: Summary of Whole Exome Sequencing results 
Details of the four genes containing bi-allelic mutations to fit an autosomal recessive model 
of inheritance. Location of the mutations is given, with impact prediction (Sift, Polyphen2, 
Condel), CADD scores, identification in sequencing databases (dbSNP147, EVS ALL, 
ExAC) and gene function. Abbreviations:  pos: amino acid position; AA: amino acids; del: 
deleterious; tol: tolerated; Prob D: probably damaging; B: benign; neut: neutral; CADD: 
Combined Annotation Dependent Depletion; CAF: complete allele frequency; EVS: Exome 
Variant Server; ExAC: Exome Aggregation Consortium. 
 
Symbol Transcript feature Allele Variant Pos 
A
A codons exon Sift Polyphen2 Condel 
CADD 
Score 
IRF8 ENST00000268638 A 
missens
e  
291 R/Q 
cGg/cA
g 7/9 del (0) 
Prob D 
(0.997) 
del 
(0.911) 36 
IRF8 ENST00000268638 T 
missens
e  
83 R/C Cgc/Tgc 3/9 del (0) 
Prob D 
(0.999) 
del 
(0.935) 27.8 
TTN ENST00000360870 T 
missens
e  
483 A/T Gcc/Acc 9/46 - B (0.181) - 14.19 
TTN ENST00000360870 A 
missens
e  
1890 R/C Cgc/Tgc 28/46 - 
Prob D 
(0.996) - 11.01 
CSPG4 ENST00000308508 T 
missens
e  
379 G/S 
Ggc/Ag
c 
3/10 tol (0.08) 
Poss D 
(0.734) 
del 
(0.569) 16.24 
CSPG4 ENST00000308508 C 
missens
e  
247 N/S aAt/aGt 3/10 del (0) 
Prob D 
(0.999) 
del 
(0.935) 15.29 
OR6N1 ENST00000335094 T 
missens
e  
7 S/N 
aGc/aA
c 
1/1 tol (0.05) B (0.035) 
neut 
(0.347) 14.28 
OR6N1 ENST00000335094 T 
missens
e  
219 V/M Gtg/Atg 1/1 
tol 
(0.11) B (0.089) 
neut 
(0.278) 1.09 
 
 
  
Symbol Chromosome position SNP ID dbSNP147_CAF EVS ALL AF 
ExAC AF 
NFE Gene and function 
IRF8 16; 85952293 - - - - 
IRF8 
IRF8 16; 85942668 - - - - 
TTN 2; 179658220 rs34337578 - - 6.00078E-05 Titin: a large abundant 
protein of striated muscle, 
mutated in familial 
hypertrophic cardio-
myopathy 9 
TTN 2; 179640923 rs146496197 0.000599 0.00107643 0.000179813 
CSPG4 15; 75982271 rs141212136 - - 0.00420603 Chondroitin sulphate 
proteoglycan 4: an integral 
membrane protein 
expressed on human 
malignant melanoma cells 
CSPG4 15; 75980521 - - - - 
OR6N1 1; 158736453 - - - - Olfactory Receptor Family 
6 Subfamily N Member 1  OR6N1 1; 158735818 rs368576348 - 0.000153775 5.99377E-05 
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Table S5: Pathway annotations for differentially expressed genes 
Summary of gene ontology (GO) terms identified as significantly enriched (p<0.01) after 
hyper-geometric testing differentially regulated transcripts as described in Figure S3. 
 
CELL TYPE GOBPID P VALUE Hits 
in DE 
gene 
lists 
Hits 
in 
Nano 
panel 
TERM 
UP in 
Neutrophils 
GO:0016045 0.002222326 4 9 detection of bacterium 
GO:0098543 0.003511831 4 10 detection of other organism 
GO:0051606 0.01750708 4 15 detection of stimulus 
GO:0002227 0.005914357 3 6 innate immune response in mucosa 
GO:0002385 0.021320939 3 9 mucosal immune response 
GO:0050832 0.037848665 3 11 defense response to fungus 
GO:0032490 0.043814273 2 5 detection of molecule of bacterial 
origin 
DOWN in 
Neutrophils 
GO:0019722 0.04642981 6 23 calcium-mediated signaling 
GO:0031343 0.037845887 6 22 positive regulation of cell killing 
GO:0001912 0.018476463 6 19 positive regulation of leukocyte 
mediated cytotoxicity 
GO:0070228 0.018476463 6 19 regulation of lymphocyte apoptotic 
process 
GO:0033628 0.00339839 5 10 regulation of cell adhesion 
mediated by integrin 
GO:0050848 0.044890105 4 12 regulation of calcium-mediated 
signaling 
GO:0034123 0.040849279 3 7 positive regulation of toll-like 
receptor signaling pathway 
GO:0072604 0.040849279 3 7 interleukin-6 secretion 
GO:0033630 0.013957043 3 5 positive regulation of cell adhesion 
mediated by integrin 
GO:0033631 0.013957043 3 5 cell-cell adhesion mediated by 
integrin 
GO:0045085 0.039491547 2 3 negative regulation of interleukin-2 
biosynthetic process 
UP in B 
cells 
GO:0002684 0.017596268 18 291 positive regulation of immune 
system process 
GO:0009617 0.03412948 9 154 response to bacterium 
GO:0098542 0.005561691 9 118 defense response to other 
organism 
GO:0002683 0.004999421 8 94 negative regulation of immune 
system process 
GO:0032496 0.049689683 7 112 response to lipopolysaccharide 
GO:0050663 0.021072203 6 73 cytokine secretion 
GO:0001818 0.016093398 6 69 negative regulation of cytokine 
production 
GO:0050777 0.007877398 5 42 negative regulation of immune 
response 
GO:0002698 0.003468525 5 35 negative regulation of immune 
effector process 
GO:1903556 0.010132174 3 15 negative regulation of tumor 
necrosis factor superfamily cytokine 
GO:0034121 0.008273739 3 14 regulation of toll-like receptor 
signaling pathway 
GO:0043409 0.045672724 2 11 negative regulation of MAPK 
cascade 
GO:0050832 0.045672724 2 11 defense response to fungus 
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GO:0019730 0.038093783 2 10 antimicrobial humoral response 
GO:0032703 0.038093783 2 10 negative regulation of interleukin-2 
production 
GO:0019731 0.031067207 2 9 antibacterial humoral response 
GO:0032753 0.031067207 2 9 positive regulation of interleukin-4 
production 
GO:0034123 0.018835046 2 7 positive regulation of toll-like 
receptor signaling pathway 
GO:0019732 0.002907265 2 3 antifungal humoral response 
DOWN in B 
cells 
GO:0001819 0.031462576 11 149 positive regulation of cytokine 
production 
GO:0000165 0.00577869 11 120 regulation of MAPK cascade 
GO:0043410 0.02274156 9 105 positive regulation of MAPK 
cascade 
GO:0010629 0.043425774 8 98 negative regulation of gene 
expression 
GO:0009890 0.008159741 9 90 negative regulation of biosynthetic 
process 
GO:0070374 0.002877251 7 49 positive regulation of ERK1 and 
ERK2 cascade 
GO:0032733 0.043252057 3 19 positive regulation of interleukin-10 
production 
GO:0032757 0.043252057 3 19 positive regulation of interleukin-8 
production 
GO:0000060 0.00926014 3 11 protein import into nucleus, 
translocation 
GO:0042033 0.042535558 2 8 chemokine biosynthetic process 
GO:0050755 0.042535558 2 8 chemokine metabolic process 
Up in NK 
cells 
GO:0009620 0.029872817 4 21 response to fungus 
GO:0032757 0.021062229 4 19 positive regulation of interleukin-8 
production 
GO:0002227 0.043980484 2 6 innate immune response in mucosa 
GO:0002523 0.043980484 2 6 leukocyte migration involved in 
inflammatory response 
GO:0090196 0.030441746 2 5 regulation of chemokine secretion 
GO:0019732 0.009848599 2 3 antifungal humoral response 
GO:0060340 0.009848599 2 3 positive regulation of type I 
interferon-mediated signaling 
pathway 
DOWN in 
NK cells 
GO:0006952 0.035815526 14 392 defense response 
GO:0007166 0.038153717 13 347 cell surface receptor signaling 
pathway 
GO:0019222 0.034816385 13 344 regulation of metabolic process 
GO:0034097 0.035519791 10 226 response to cytokine 
GO:0031349 0.019692748 8 144 positive regulation of defense 
response 
GO:0002757 0.026158083 7 121 immune response-activating signal 
transduction 
GO:0009615 0.024536277 6 92 response to virus 
GO:0034341 0.005058186 6 67 response to interferon-gamma 
GO:0002819 0.014707289 5 59 regulation of adaptive immune 
response 
GO:0002221 0.011776317 5 56 pattern recognition receptor 
signaling pathway 
GO:0002224 0.007846035 5 51 toll-like receptor signaling pathway 
GO:0001959 0.020746086 4 42 regulation of cytokine-mediated 
signaling pathway 
GO:0034138 0.048907012 3 32 toll-like receptor 3 signaling 
pathway 
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GO:0032663 0.041374314 3 30 regulation of interleukin-2 
production 
GO:0034340 0.041374314 3 30 response to type I interferon 
GO:0034134 0.034503322 3 28 toll-like receptor 2 signaling 
pathway 
GO:0034146 0.015719153 3 21 toll-like receptor 5 signaling 
pathway 
GO:0033673 0.010132174 3 18 negative regulation of kinase 
activity 
GO:0045620 0.044509817 2 13 negative regulation of lymphocyte 
differentiation 
GO:0060330 0.026912182 2 10 regulation of response to interferon-
gamma 
GO:0060334 0.026912182 2 10 regulation of interferon-gamma-
mediated signaling pathway 
GO:1904029 0.021869613 2 9 regulation of cyclin-dependent 
protein kinase activity 
UP in T cells GO:0019725 0.035980664 10 75 cellular homeostasis 
GO:0050832 0.005737437 4 11 defense response to fungus 
GO:0034123 0.010551681 3 7 positive regulation of toll-like 
receptor signaling pathway 
GO:0034145 0.015142508 2 3 positive regulation of toll-like 
receptor 4 signaling pathway 
GO:0002430 0.005295584 2 2 complement receptor mediated 
signaling pathway 
DOWN in T 
cells 
GO:0010629 0.000984353 11 98 negative regulation of gene 
expression 
GO:0002221 0.025335714 6 56 pattern recognition receptor 
signaling pathway 
GO:0002224 0.016293373 6 51 toll-like receptor signaling pathway 
GO:0031098 0.027738514 5 42 stress-activated protein kinase 
signaling cascade 
GO:0032640 0.022768595 5 40 tumor necrosis factor production 
GO:0034142 0.022768595 5 40 toll-like receptor 4 signaling 
pathway 
GO:0034138 0.008831489 5 32 toll-like receptor 3 signaling 
pathway 
GO:0031663 0.004850777 5 28 lipopolysaccharide-mediated 
signaling pathway 
GO:0035666 0.027070881 4 28 TRIF-dependent toll-like receptor 
signaling pathway 
GO:0042770 0.01153942 4 22 signal transduction in response to 
DNA damage 
GO:0034146 0.009723364 4 21 toll-like receptor 5 signaling 
pathway 
GO:0034166 0.04945423 3 20 toll-like receptor 10 signaling 
pathway 
GO:0072678 0.032136155 3 17 T cell migration 
GO:1902806 0.032136155 3 17 regulation of cell cycle G1/S phase 
transition 
GO:0032720 0.0151558 3 13 negative regulation of tumor 
necrosis factor production 
GO:0042771 0.00693088 3 10 intrinsic apoptotic signaling 
pathway in response to DNA 
damage 
GO:0042090 0.02402828 2 6 interleukin-12 biosynthetic process 
GO:0045075 0.02402828 2 6 regulation of interleukin-12 
biosynthetic process 
GO:0031032 0.01645086 2 5 actomyosin structure organization 
GO:0032692 0.01645086 2 5 negative regulation of interleukin-1 
production 
GO:0045084 0.01645086 2 5 positive regulation of interleukin-12 
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biosynthetic process 
Up in NK 
cells 
GO:0009620 0.029872817 4 21 response to fungus 
GO:0032757 0.021062229 4 19 positive regulation of interleukin-8 
production 
GO:0002227 0.043980484 2 6 innate immune response in mucosa 
GO:0002523 0.043980484 2 6 leukocyte migration involved in 
inflammatory response 
GO:0090196 0.030441746 2 5 regulation of chemokine secretion 
GO:0019732 0.009848599 2 3 antifungal humoral response 
GO:0060340 0.009848599 2 3 positive regulation of type I 
interferon-mediated signaling 
pathway 
DOWN in 
NK cells 
GO:0006952 0.035815526 14 392 defense response 
GO:0007166 0.038153717 13 347 cell surface receptor signaling 
pathway 
GO:0019222 0.034816385 13 344 regulation of metabolic process 
GO:0034097 0.035519791 10 226 response to cytokine 
GO:0031349 0.019692748 8 144 positive regulation of defense 
response 
GO:0002757 0.026158083 7 121 immune response-activating signal 
transduction 
GO:0009615 0.024536277 6 92 response to virus 
GO:0034341 0.005058186 6 67 response to interferon-gamma 
GO:0002819 0.014707289 5 59 regulation of adaptive immune 
response 
GO:0002221 0.011776317 5 56 pattern recognition receptor 
signaling pathway 
GO:0002224 0.007846035 5 51 toll-like receptor signaling pathway 
GO:0001959 0.020746086 4 42 regulation of cytokine-mediated 
signaling pathway 
GO:0034138 0.048907012 3 32 toll-like receptor 3 signaling 
pathway 
GO:0032663 0.041374314 3 30 regulation of interleukin-2 
production 
GO:0034340 0.041374314 3 30 response to type I interferon 
GO:0034134 0.034503322 3 28 toll-like receptor 2 signaling 
pathway 
GO:0034146 0.015719153 3 21 toll-like receptor 5 signaling 
pathway 
GO:0033673 0.010132174 3 18 negative regulation of kinase 
activity 
GO:0045620 0.044509817 2 13 negative regulation of lymphocyte 
differentiation 
GO:0060330 0.026912182 2 10 regulation of response to interferon-
gamma 
GO:0060334 0.026912182 2 10 regulation of interferon-gamma-
mediated signaling pathway 
GO:1904029 0.021869613 2 9 regulation of cyclin-dependent 
protein kinase activity 
UP in T cells GO:0019725 0.035980664 10 75 cellular homeostasis 
GO:0050832 0.005737437 4 11 defense response to fungus 
GO:0034123 0.010551681 3 7 positive regulation of toll-like 
receptor signaling pathway 
GO:0034145 0.015142508 2 3 positive regulation of toll-like 
receptor 4 signaling pathway 
GO:0002430 0.005295584 2 2 complement receptor mediated 
signaling pathway 
DOWN in T 
cells 
GO:0010629 0.000984353 11 98 negative regulation of gene 
expression 
GO:0002221 0.025335714 6 56 pattern recognition receptor 
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signaling pathway 
GO:0002224 0.016293373 6 51 toll-like receptor signaling pathway 
GO:0031098 0.027738514 5 42 stress-activated protein kinase 
signaling cascade 
GO:0032640 0.022768595 5 40 tumor necrosis factor production 
GO:0034142 0.022768595 5 40 toll-like receptor 4 signaling 
pathway 
GO:0034138 0.008831489 5 32 toll-like receptor 3 signaling 
pathway 
GO:0031663 0.004850777 5 28 lipopolysaccharide-mediated 
signaling pathway 
GO:0035666 0.027070881 4 28 TRIF-dependent toll-like receptor 
signaling pathway 
GO:0042770 0.01153942 4 22 signal transduction in response to 
DNA damage 
GO:0034146 0.009723364 4 21 toll-like receptor 5 signaling 
pathway 
GO:0034166 0.04945423 3 20 toll-like receptor 10 signaling 
pathway 
GO:0072678 0.032136155 3 17 T cell migration 
GO:1902806 0.032136155 3 17 regulation of cell cycle G1/S phase 
transition 
GO:0032720 0.0151558 3 13 negative regulation of tumor 
necrosis factor production 
GO:0042771 0.00693088 3 10 intrinsic apoptotic signaling 
pathway in response to DNA 
damage by p53 
GO:0042090 0.02402828 2 6 interleukin-12 biosynthetic process 
GO:0045075 0.02402828 2 6 regulation of interleukin-12 
biosynthetic process 
GO:0031032 0.01645086 2 5 actomyosin structure organization 
GO:0032692 0.01645086 2 5 negative regulation of interleukin-1 
production 
GO:0045084 0.01645086 2 5 positive regulation of interleukin-12 
biosynthetic process 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20 
Table S6: Differentially expressed genes shared in K108E and 83C/291Q 
Genes identified as dysregulated (and IRF8-bound in the second column) both in the patient 
bearing IRF8K108E/K108E by RNA-Seq of PBMC14 and the patient with IRF8R83C/R291Q by 
Nanostring nCounter analysis of FACs-purified lymphoid subsets or density centrifugation 
purification of neutrophils. 
 
Shared Shared  IRF8 bound 
CAMP CCL4 
CCL3 CCR5 
CCL4 CD1D 
CCR5 CD244 
CD19 CXCR6 
CD1D GPR183 
CD24 LTF 
CD244 MALT1 
CD28 MS4A1 
CD5 NFATC2 
CD8A S100A8 
CEACAM8 S1PR1 
CXCR6 SLC2A1 
FADD TAGAP 
FKBP5 TGFBI 
FYN  
GPR183  
GZMB  
KIR3DL2  
LILRB4  
LTF  
MALT1  
MAPK11  
MS4A1  
MUC1  
NFATC2  
S100A8  
S100A9  
S1PR1  
SLAMF1  
SLC2A1  
TAGAP  
TGFBI  
TIGIT  
TLR3  
TNFRSF10C  
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Table S7: Antibodies used for flow cytometry. 
Antibody, fluorochrome, clone and manufacturer of antibodies used in flow cytometry 
 
Antigen Fluorochrome Clone Manufacturer 
CCR7 FITC G043H7 Biolegend 
CD117 BV605 104D2 BD Biosciences (BD) 
CD11c BV421/AF700 B-ly6 BD 
CD123 PerCP-Cy5.5 7G3 BD 
CD127 APC A019D5 Biolegend 
CD14 BV650 M5E2 Biolegend 
CD141 APC AD5-14H12 Miltenyi 
CD10 BV650 HI10A BD 
CD15 FITC MMA BD 
CD159a APC Z199 BeckmanCoulter 
CD16 PE-CF-594/APC-H7//PE-Dazzle-594/PE-Cy7 3G8/3G8/3G8/B73.1 BD/BD/Biolegend/BD 
CD19 PE-CF-594/PE/FITC HIB19/HIB19/4G7 BD/BD/BD 
CD1c PE-Cy7 L161 Biolegend 
CD206 PE 19.2 BD 
CD21 APC B-Ly4 BD 
CD24 FITC ML5 BD 
CD25 BV650 BC96 Biolegend 
CD27 BV421/V500 O323/M-T271 Biolegend/BD 
CD3 FITC/PerCP-Cy5.5/APC-H7/PE 
SK7(Leu4)/SK7(Leu4)/S
K7/SK7(Leu9) BD/BD/BD/BD 
CD34 BV605/APCCy7 581 Biolegend 
CD38 PE-Cy7 HB7 BD 
CD4 PE/BV420 SK3 (Leu3a)/RPA-T4 BD/Biolegend 
CD45 AF700/V500 HI30 Biolegend/BD 
CD45RA BV510 HI100 Biolegend 
CD5 PE UCHT2 Biolegend 
CD56 FITC/APC NCAM16.2 BD 
CD57 eF450 TB01 eBioscience 
CD69 PE-Cy7 FN50 BD 
CD8 APC-Cy7 SK1 BD 
CD90 PerCP-Cy5.5 5.00E+10 Biolegend 
CXCR3 PE-Cy7 1C6/CXCR3 BD 
HLA-DR V500/AF700 G46-6 BD 
IFNg APC-Cy7 4S.B3 Biolegend 
IgD APC-H7 IA6-2 BD 
IgM PerCP-Cy5.5 G20-127 BD 
IL-17a APC eBio64CAP17 eBioscience 
IL-22 PE 142928 R&D Systems 
IL-4 PE-Cy7 8D4-8 eBioscience 
IRF8 PerCP-eFluor710 V3GYWCH eBioscience 
KIR1, 2, 
3 PE EB6B/GL183/Z27.3.7 BeckmanCoulter 
Lang PE DCGM4 BeckmanCoulter 
NKG2D PerCP-Cy5.5 1D11 BD 
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